A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.

• Country France, United States
• organs None
• Specialty None

Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment Evaluation after 4 weeks of treatment or at end of treatment if it occurs before. Efficacy will be defined as objective responses; complete and partial response.

• Country France
• organs None
• Specialty None

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis This is a 12 weeks study aimed at assessing the safety and efficacy of 2 doses of AB1010 in patients suffering from indolent systemic mastocytosis with handicap.

• Country None
• organs None
• Specialty None